Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Combining Factorial and MAMS designs
Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11
c4c General Assembly
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Severity and Outcomes of Dengue in Hospitalized Jamaican Children in 2018–2019 During an Epidemic Surge in the Americas
🇮🇹 Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5 agli 11 anni
The D3 trial is open and recruiting fast!
🇬🇧 Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11
SHIELD trial screens first two patients
EMA updates guideline on the treatment of bacterial infections
Seasonal patterns of SARS-CoV-2 transmission in secondary schools: a modelling study
Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine
The Penta Early Career Researchers (ECRs) have held the first Penta Cafè!
PediCAP surpasses 25% patient recruitment milestone
Penta ID Network Meeting (PIM) 2022
Youth engagement and participation in clinical trials
